Arcus Biosciences Inc. (RCUS)
NYSE: RCUS
· Real-Time Price · USD
8.57
0.21 (2.51%)
At close: Jul 02, 2025, 3:59 PM
8.85
3.21%
After-hours: Jul 02, 2025, 06:00 PM EDT
2.51% (1D)
Bid | 8.55 |
Market Cap | 907.96M |
Revenue (ttm) | 141M |
Net Income (ttm) | -391M |
EPS (ttm) | -4.23 |
PE Ratio (ttm) | -2.03 |
Forward PE | -1.81 |
Analyst | Buy |
Ask | 8.85 |
Volume | 549,447 |
Avg. Volume (20D) | 1,262,686 |
Open | 8.39 |
Previous Close | 8.36 |
Day's Range | 8.37 - 8.80 |
52-Week Range | 6.50 - 18.98 |
Beta | 0.83 |
About RCUS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RCUS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RCUS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Arcus Biosciences Inc. is scheduled to release its earnings on Aug 7, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-1.35%
Arcus Biosciences shares are trading lower after t...
Unlock content with
Pro Subscription
4 months ago
-16.34%
Arcus Biosciences shares are trading lower after the company announced a $150 million stock offering.

3 weeks ago · https://www.defenseworld.net
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 7,872 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 11.3% during the 4th quarter, according to the...

3 months ago · seekingalpha.com
Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term CatalystsArcus Biosciences presents a high-risk speculation with significant upcoming catalysts, despite recent stock declines and Gilead's exit from the ARC-10 trial. Gilead's continued investment and board p...